Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials
Paul E Sax,David Wohl,Michael T Yin,Frank Post,Edwin DeJesus,Michael Saag,Anton Pozniak,Melanie Thompson,Daniel Podzamczer,Jean Michel Molina,Shinichi Oka,Ellen Koenig,Benoit Trottier,Jaime Andrade-Villanueva,Gordon Crofoot,Joseph M Custodio,Andrew Plummer,Lijie Zhong,Huyen Cao,Hal Martin,Christian Callebaut,Andrew K Cheng,Marshall W Fordyce,Scott McCallister,GS-US-292-0104/0111 Study Team,C Achenbach,F Ajana,B Akil,H Albrecht,J Andrade Villanueva,J Angel,A Antela Lopez,J Arribas Lopez,A Avihingsanon,D Baker,N Bellos,P Benson,J Berenguer,I Bica,A Blaxhult,M Bloch,P Brachman,I Brar,K Brinkman,C Brinson,B Brown,J Brunetta,J Burack,T Campbell,M Cavassini,A Cheret,P Chetchotisakd,A Clarke,B Clotet,N Clumeck,C Cohen,P Cook,L Cotte,D Coulston,M Crespo,C Creticos,G Crofoot,F Cruickshank,J Cunha,E Daar,E DeJesus,J De,M Doroana,R Dretler,M Dube,J Durant,H Edelstein,R Elion,J Fehr,R Finlayson,D Fish,J Flamm,S Follansbee,H Furrer,F Garcia,J Gatell Artigas,J Gathe,S Gilroy,E Gordon,P Grant,R Grossberg,C Hare,T Hawkins,R Hengel,K Henry,A Hite,G Huhn,M Johnson,K Kasper,C Katlama,S Kiertiburanakul,J M Kilby,C Kinder,D Klein,H Knobel,E Koenig,M Kozal,R Landovitz,J Larioza,A Lazzarin,R LeBlanc,B LeBouche,S Lewis,S Little,C Lucasti,C Martorell,C Mayer,C McDonald,J McGowan,M McKellar,G McLeod,A Mills,J-M Molina,G Moyle,M Mullen,C Mussini,R Nahass,C Newman,S Oka,H Olivet,C Orkin,P Ortolani,O Osiyemi,F Palella,P Palmieri,D Parks,A Petroll,G Pialoux,G Pierone,D Podzamczer Palter,C Polk,R Pollard,F Post,A Pozniak,D Prelutsky,A Rachlis,M Ramgopal,B Rashbaum,W Ratanasuwan,R Redfield,G Reyes Teran,J Reynes,G Richmond,A Rieger,B Rijnders,W Robbins,A Roberts,J Ross,P Ruane,R Rubio Garcia,M Saag,J Santana,R Sarmento,B Schmied,T Schmidt,S Schrader,A Scribner,S Segal,P Shalit,D Shamblaw,C Shikuma,K Siripassorn,J Slim,L Sloan,D Smith,K Squires,D Stein,J Stephens,K Supparatpinyo,K Tashima,S Taylor,P Tebas,E Teofilo,A Thalme,M Thompson,W Towner,T Treadwell,B Trottier,T Vanig,N Vetter,P Viale,G Voskuhl,B Wade,S Walmsley,D Ward,L Waters,D Wheeler,A Wilkin,T Wilkin,E Wilkins,T Wills,D Wohl,M Wohlfeiler,K Workowski,B Yangco,Y Yazdanpanah,M Yin,B Young,A Zolopa,C Zurawski
DOI: https://doi.org/10.1016/S0140-6736(15)60616-X
2015-06-27
Abstract:Background: Tenofovir disoproxil fumarate can cause renal and bone toxic effects related to high plasma tenofovir concentrations. Tenofovir alafenamide is a novel tenofovir prodrug with a 90% reduction in plasma tenofovir concentrations. Tenofovir alafenamide-containing regimens can have improved renal and bone safety compared with tenofovir disoproxil fumarate-containing regimens. Methods: In these two controlled, double-blind phase 3 studies, we recruited treatment-naive HIV-infected patients with an estimated creatinine clearance of 50 mL per min or higher from 178 outpatient centres in 16 countries. Patients were randomly assigned (1:1) to receive once-daily oral tablets containing 150 mg elvitegravir, 150 mg cobicistat, 200 mg emtricitabine, and 10 mg tenofovir alafenamide (E/C/F/tenofovir alafenamide) or 300 mg tenofovir disoproxil fumarate (E/C/F/tenofovir disoproxil fumarate) with matching placebo. Randomisation was done by a computer-generated allocation sequence (block size 4) and was stratified by HIV-1 RNA, CD4 count, and region (USA or ex-USA). Investigators, patients, study staff, and those assessing outcomes were masked to treatment group. All participants who received one dose of study drug were included in the primary intention-to-treat efficacy and safety analyses. The main outcomes were the proportion of patients with plasma HIV-1 RNA less than 50 copies per mL at week 48 as defined by the the US Food and Drug Adminstration (FDA) snapshot algorithm (pre-specified non-inferiority margin of 12%) and pre-specified renal and bone endpoints at 48 weeks. These studies are registered with ClinicalTrials.gov, numbers NCT01780506 and NCT01797445. Findings: We recruited patients from Jan 22, 2013, to Nov 4, 2013 (2175 screened and 1744 randomly assigned), and gave treatment to 1733 patients (866 given E/C/F/tenofovir alafenamide and 867 given E/C/F/tenofovir disoproxil fumarate). E/C/F/tenofovir alafenamide was non-inferior to E/C/F/tenofovir disoproxil fumarate, with 800 (92%) of 866 patients in the tenofovir alafenamide group and 784 (90%) of 867 patients in the tenofovir disoproxil fumarate group having plasma HIV-1 RNA less than 50 copies per mL (adjusted difference 2·0%, 95% CI -0·7 to 4·7). Patients given E/C/F/tenofovir alafenamide had significantly smaller mean serum creatinine increases than those given E/C/F/tenofovir disoproxil fumarate (0·08 vs 0·12 mg/dL; p<0·0001), significantly less proteinuria (median % change -3 vs 20; p<0·0001), and a significantly smaller decrease in bone mineral density at spine (mean % change -1·30 vs -2·86; p<0·0001) and hip (-0·66 vs -2·95; p<0·0001) at 48 weeks. Interpretation: Through 48 weeks, more than 90% of patients given E/C/F/tenofovir alafenamide or E/C/F/tenofovir disoproxil fumarate had virological success. Renal and bone effects were significantly reduced in patients given E/C/F/tenofovir alafenamide. Although these studies do not have the power to assess clinical safety events such as renal failure and fractures, our data suggest that E/C/F/tenofovir alafenamide will have a favourable long-term renal and bone safety profile. Funding: Gilead Sciences.